Cleopatra Hospital CoCAI:CLHO +3.66%88 EBITDA Margin % is 21.16% as of Mar. 2026, which is 14% below its 10-year median of 24.68. GuruFocus rates CAI:CLHO with a GF Score™ of 88/100 and a GF Value™ of E£13.81 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 668 Healthcare Providers & Services companies, Cleopatra Hospital Co ranks better than 82.34% on this metric.
Cleopatra Hospital Co (CAI:CLHO) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Cleopatra Hospital Co EBITDA Margin % Related Terms
Cleopatra Hospital Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Cleopatra Hospital Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CAI:CLHO vs HCA, THC, DVA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Cleopatra Hospital Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cleopatra Hospital Co EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Cleopatra Hospital Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Cleopatra Hospital Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cleopatra Hospital Co (CAI:CLHO) has a EBITDA Margin % of 21.16% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cleopatra Hospital Co and its competitors. This is 14% below median its historical median of 24.68. Over the past decade, Cleopatra Hospital Co's EBITDA Margin % has ranged from 23.31 to 33.82. According to the industry distribution chart, Cleopatra Hospital Co ranks #118 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 17.7%.
Is Cleopatra Hospital Co's EBITDA Margin % too high?
Cleopatra Hospital Co's current EBITDA Margin % of 21.16% is 14% below median its 10-year median of 24.68. Over the past 10 years, this metric has ranged from a low of 23.31 to a high of 33.82. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. Cleopatra Hospital Co's value of 21.16% is 107.2% above this industry median. Based on the distribution chart, Cleopatra Hospital Co ranks #118 out of 668 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Cleopatra Hospital Co has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cleopatra Hospital Co's EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Cleopatra Hospital Co ranks #118 out of 668 companies for EBITDA Margin %. This places Cleopatra Hospital Co in the top 18% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 10.21. Cleopatra Hospital Co's value of 21.16% is 107.2% above this benchmark. Historically, Cleopatra Hospital Co's own EBITDA Margin % has ranged from 23.31 to 33.82 over the past decade. While the company's 10-year median is 24.68 vs. the industry median of 10.21, Cleopatra Hospital Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cleopatra Hospital Co's current EBITDA Margin % of 21.16% is 107.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cleopatra Hospital Co and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cleopatra Hospital Co's current EBITDA Margin % is 21.16%, which is 14% below median its own 10-year median of 24.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cleopatra Hospital Co stock overvalued right now?
Based on GuruFocus' analysis, Cleopatra Hospital Co (CAI:CLHO) is currently considered Modestly Overvalued. The stock's GF Value™ is E£13.81, compared to a current price of E£17.00 — trading 23.1% above its estimated fair value. The current EBITDA Margin % is 21.16%, which is 14% below median its 10-year median of 24.68 and 107.2% above the Healthcare Providers & Services industry median of 10.21. Cleopatra Hospital Co's overall GF Score™ is 88/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Cleopatra Hospital Co (CAI:CLHO), the current EBITDA Margin % is 21.16% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cleopatra Hospital Co (CAI:CLHO) Overvalued in 2026?
Based on GuruFocus' analysis, Cleopatra Hospital Co stock appears to be overvalued.
The current stock price of E£17.00 is trading 23.1% above its estimated GF Value™ of E£13.81.
GuruFocus considers Cleopatra Hospital Co to be Modestly Overvalued.
Key valuation signals for CAI:CLHO:
EBITDA Margin %: 21.16% (14% below median its 10-year median of 24.68)
GF Value™: E£13.81 vs. price of E£17.00 (23.1% above fair value)
Industry Position: 107.2% above the Healthcare Providers & Services median (#118 of 668)
No single metric tells the full story. See the CAI:CLHO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cleopatra Hospital Co establishes a private hospital to provide modern health and medical services, in addition to medical care for inpatients. The company's segments include Cleopatra Hospital Company, Cairo Specialised Hospital, Nile Badrawy Hospital, Al Shrouk Hospital, CHG Medical Services, CHG Pharma for Pharmacy Management, CHG for Hospitals Company, Queens Hospital, ElKateb Hospital, Bedaya El Gedida Company for Medical Centers and Hospitals, CHG SKY Hospital, and Cleopatra Heaven.
88GF Score
Get the complete analysis for CAI:CLHO
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:CLHO has been successfully added to your 
